drugset / Trial / NCT06904040
A Single-center Study of CM313 in Patients With Pemphigus
NaSingle-groupOpen-labelTreatment
Summary
A prospective, single-center, single-arm clinical study aimed to explore the efficacy and safety of the anti-CD38 monoclonal antibody CM313 combined with low-dose glucocorticoids in patients with pemphigus.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2027-10-31
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMROTATUG | Monoclonal antibody | 600 mg | — |